Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone plus hydroxychloroquine vs hydroxychloroquine alone for early treatment of severe COVID-19 ARDS
2020-001333-13Phase 3Terminated
- Sponsor
- Groupe hospitalier Paris Saint-Joseph
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) comparing Dexamethasone + hydroxychloroquine with Hydroxychloroquine alone (2 arms). Primary endpoint: Mortality at day 28. Started Apr 2020; status: terminated.
02
Drugs
dexamethasonehydroxychloroquine
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001333-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001333-13.